Multi-centre, open-label extension trial of treatment with ZD1839 (Iressa) in patients who have been treated in other ZD1839 clinical trials and may benefit from continued monotherapy ZD 1839.
Phase of Trial: Phase III
Latest Information Update: 01 May 2009
At a glance
- Drugs Gefitinib (Primary)
- Indications Cancer
- Focus Adverse reactions; Registrational
- Sponsors AstraZeneca
- 01 May 2009 Actual end date changed from 1 Mar 2003 to 1 Oct 2003.
- 04 Apr 2008 New trial record.